GENFIT Share Price Euronext Paris
Stocks
FR0004163111
Biotechnology & Medical Research
OTC Markets Traded|
Real-time Estimate
Other stock markets
|
||
| 13.55 EUR | 0.00% |
|
| 07-03 | Genfit soars on news of U.S. reimbursement for a product |  |
| 07-03 | Genfit's Liver Disease Blood Test Approved for US Medicare Reimbursement | MT |
| Market Cap | 679M 773M 634M 582M 1.09B 74.05B 1.12B 7.52B 2.94B 36.64B 2.9B 2.84B 127B | P/E 2026 * |
34.1x | P/E 2027 * | 87.6x |
|---|---|---|---|---|---|
| Enterprise Value | 628M 715M 586M 538M 1.01B 68.48B 1.03B 6.95B 2.72B 33.89B 2.68B 2.63B 117B | EV / Sales 2026 * |
6.27x | EV / Sales 2027 * | 4.94x |
| Free-Float |
86.88% | Yield 2026 * |
-
| Yield 2027 * | - |
| Manager | Title | Age | Since |
|---|---|---|---|
Pascal Prigent
CEO | Chief Executive Officer | 58 | 15/09/2019 |
Thomas Baetz
DFI | Director of Finance/CFO | 52 | 21/04/2021 |
Pejvack Motlagh
CTO | Chief Tech/Sci/R&D Officer | - | 26/11/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | 15/06/2017 | |
| Director/Board Member | 54 | 14/09/1999 | |
| Director/Board Member | 58 | 15/06/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.61% | +1.91% | +1.70% | +13.91% | 47.88B | |
| -1.60% | -1.29% | +385.56% | +603.70% | 39.09B | |
| -0.98% | +2.68% | +11.10% | +45.34% | 36.75B | |
| +1.90% | +22.79% | +25.18% | +9.47% | 40.55B | |
| +1.47% | +4.90% | +6.48% | +43.52% | 27.96B | |
| -0.94% | -1.23% | - | - | 16.77B | |
| +2.44% | +10.02% | +29.11% | +129.56% | 15.94B | |
| +0.18% | -1.46% | +4.92% | +10.14% | 13.55B | |
| -1.14% | +6.94% | -6.05% | -29.33% | 13.81B | |
| Average | +0.40% | +4.66% | +57.25% | +103.29% | 28.03B | |
| Weighted average by Cap. | +0.54% | +5.06% | +73.07% | +124.52% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 100M 114M 93.53M 85.83M 161M 10.92B 165M 1.11B 434M 5.4B 428M 419M 18.68B | 124M 141M 116M 106M 199M 13.52B 204M 1.37B 537M 6.69B 530M 519M 23.13B |
| Net income | 22.88M 26.04M 21.35M 19.6M 36.69M 2.49B 37.59M 253M 99.03M 1.23B 97.75M 95.63M 4.27B | 6.8M 7.74M 6.35M 5.83M 10.9M 741M 11.17M 75.27M 29.43M 367M 29.05M 28.42M 1.27B |
| Net Debt | -51.12M -58.17M -47.71M -43.79M -81.97M -5.57B -83.99M -566M -221M -2.76B -218M -214M -9.53B | -66.17M -75.31M -61.77M -56.69M -106M -7.21B -109M -732M -286M -3.57B -283M -277M -12.34B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
